Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00134186 · ClinicalTrials.gov registry record · Phase 2
Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer
A Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms, sponsored by Pharmacyclics.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT00134186: Completed Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms, sponsored by Pharmacyclics.
NCT00134186 is a Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms that has completed, run by Pharmacyclics. The registered enrollment target is 43 participants, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00134186, a Phase 2 study of Carcinoma, Renal Cell and Urogenital Neoplasms, has completed, sponsored by Pharmacyclics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).
Conditions Studied
Interventions
- DRUG motexafin gadolinium
Study Locations (1)
Texas
- Methodist Hospital - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Phase | Phase 2 |
What the finished NCT00134186 record still lists
NCT00134186 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 282-participant average among 34 other Carcinoma, Renal Cell trials with a reported enrollment target (85% lower).
The record links to 4 conditions, with Carcinoma, Renal Cell appearing as the primary indexed condition, and to 1 intervention - of which motexafin gadolinium is the first listed.
NCT00134186 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00134186 about?
NCT00134186 is a clinical study titled "Study of Motexafin Gadolinium for the Treatment of Renal Cell (Kidney) Cancer". The purpose of this study is to find out if renal cell (kidney) cancer that has spread to other parts of the body will respond to treatment with motexafin gadolinium (MGd).
What is the current status of trial NCT00134186?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants.
What conditions does trial NCT00134186 study?
This clinical trial studies the following conditions: Carcinoma, Renal Cell, Urogenital Neoplasms, Kidney Neoplasms, Urologic Neoplasms.
What interventions are being tested in trial NCT00134186?
The interventions under investigation include: motexafin gadolinium (DRUG).
Who is sponsoring clinical trial NCT00134186?
This trial is sponsored by Pharmacyclics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00134186 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Carcinoma, Renal Cell
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00134186's enrollment target sits among peer trials
43 24th of 34 higher than 11 of 34 other Carcinoma, Renal Cell trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Carcinoma, Renal Cell trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Autologous Dendritic Cell Vaccine in Kidney Cancer
RECRUITING · Phase 2
-
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
ACTIVE NOT RECRUITING · Phase 2
-
Safety and Biological Activity of TroVax® Vaccine Given With IL-2 in Renal Cell Carcinoma
COMPLETED · Phase 2
-
Safety and Toxicity Study of Sorafenib in Patients With Kidney Cancer
COMPLETED · Phase 2
-
A Study of TroVax Vaccine Given in Conjunction With IL-2 for Treatment of Stage IV Renal Cell Cancer
COMPLETED · Phase 2
-
Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM